Modelling the time course of antimalarial parasite killing: A tour of animal and human models, translation and challenges

British Journal of Clinical Pharmacology

Volumn 79, Issue 1, 2015, Pages 97-107

  Patel, Kashyap ^a   Simpson, Julie A ^b   Batty, Kevin T ^c,d   Zaloumis, Sophie ^b   Kirkpatrick, Carl M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d West Coast Institute   (Australia)

Author keywords

antimalarial chemotherapy; malaria; mechanism based model; pharmacodynamic; pharmacokinetics

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTEMISININ;

ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG SCREENING; HUMAN; LIFE CYCLE; MALARIA; MALARIA FALCIPARUM; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; PREDICTION; ANIMAL; BIOLOGICAL MODEL; COMBINATION DRUG THERAPY; DOSE CALCULATION; DRUG EFFECTS; DRUG RESISTANCE; MALARIA, FALCIPARUM; PARASITE; TIME FACTOR; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; MODELS, BIOLOGICAL; PARASITES; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85000223246     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12288     Document Type: Article

References (108)

1. World Health Organization. Global Malaria Programme: World Malaria Report. Geneva, Switzerland: World Health Organization, 2012.
2. Wells TN, Alonso PL, Gutteridge WE,. New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov 2009; 8: 879-891.
3. Baird JK,. Effectiveness of antimalarial drugs. N Engl J Med 2005; 352: 1565-1577.
4. The malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med 2011; 8: e1000402.
5. Barnes KI, Watkins WM, White NJ,. Antimalarial dosing regimens and drug resistance. Trends Parasitol 2008; 24: 127-134.
6. Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, Gbotosho GO, Watkins WM, Sibley CH, White NJ,. World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. Malar J 2007; 6: 122.
7. Holford NHG, Sheiner LB,. Understanding the dose-effect relationship-clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokin 1981; 6: 429-453.
8. Al-Sallami HS, Pavan Kumar VV, Landersdorfer CB, Bulitta JB, Duffull SB,. The time course of drug effects. Pharm Stat 2009; 8: 176-185.
9. Wright DF, Winter HR, Duffull SB,. Understanding the time course of pharmacological effect: a PKPD approach. Br J Clin Pharmacol 2011; 71: 815-823.
10. Duffull SB, Wright DF, Winter HR,. Interpreting population pharmacokinetic-pharmacodynamic analyses-a clinical viewpoint. Br J Clin Pharmacol 2011; 71: 807-814.
11. Roberts JA, Kirkpatrick CM, Lipman J,. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 2011; 66: 227-231.
12. Hoshen MB, Heinrich R, Stein WD, Ginsburg H,. Mathematical modelling of the within-host dynamics of Plasmodium falciparum. Parasitology 2000; 121: 227-235.
13. Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H,. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 2000; 121: 237-246.
14. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S,. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993; 76: 85-95.
15. Winter K, Hastings IM,. Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Antimicrob Agents Chemother 2011; 55: 3380-3392.
16. Trager W, Jensen JB,. Human malaria parasites in continuous culture. Science 1976; 193: 673-675.
17. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD,. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 1979; 16: 710-718.
18. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S,. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 2004; 3: 509-520.
19. Fivelman QL, Adagu IS, Warhurst DC,. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother 2004; 48: 4097-4102.
20. LeRoux M, Lakshmanan V, Daily JP,. Plasmodium falciparum biology: analysis of in vitro versus in vivo growth conditions. Trends Parasitol 2009; 25: 474-481.
21. Noedl H, Wongsrichanalai C, Wernsdorfer WH,. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol 2003; 19: 175-181.
22. Zaloumis S, Humberstone A, Charman SA, Price RN, Moehrle J, Gamo-Benito J, McCaw J, Jamsen KM, Smith K, Simpson JA,. Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar J 2012; 11: 303-317.
23. Berenbaum MC,. A method for testing for synergy with any number of agents. J Infect Dis 1978; 137: 122-130.
24. Chawira AN, Warhurst DC,. The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. J Trop Med Hyg 1987; 90: 1-8.
25. World Health Organization. Guidelines for the Treatment of Malaria, 2nd edn. Geneva, Switzerland: World Health Organization, 2011.
26. Nosten F, White NJ,. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007; 77: 181-192.
27. Kremsner PG, Krishna S,. Antimalarial combinations. Lancet 2004; 364: 285-294.
28. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chan Thap L,. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis 2010; 51: e82-89.
29. Vivas L, Rattray L, Stewart LB, Robinson BL, Fugmann B, Haynes RK, Peters W, Croft SL,. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J Antimicrob Chemother 2007; 59: 658-665.
30. Noedl H, Krudsood S, Leowattana W, Tangpukdee N, Thanachartwet W, Looareesuwan S, Miller RS, Fukuda M, Jongsakul K, Yingyuen K, Sriwichai S, Ohrt C, Knirsch C,. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother 2007; 51: 651-656.
31. Kelly JX, Smilkstein MJ, Brun R, Wittlin S, Cooper RA, Lane KD, Janowsky A, Johnson RA, Dodean RA, Winter R, Hinrichs DJ, Riscoe MK,. Discovery of dual function acridones as a new antimalarial chemotype. Nature 2009; 459: 270-273.
32. Obaldia N, III, Kotecka BM, Edstein MD, Haynes RK, Fugmann B, Kyle DE, Rieckmann KH,. Evaluation of artemisone combinations in Aotus monkeys infected with Plasmodium falciparum. Antimicrob Agents Chemother 2009; 53: 3592-3594.
33. Mackenstedt U, Brockelman CR, Mehlhorn H, Raether W,. Comparative morphology of human and animal malaria parasites. I. Host-parasite interface. Parasitol Res 1989; 75: 528-535.
34. Peters W,. Chemotherapy and Drug Resistance in Malaria. London: Academic Press, 1970.
35. Ager ALJ,. Rodent malaria models. In: Antimalarial Drugs 1: Biological Background, Experimental Methods, and Drug Resistance 2: Current Antimalarials and New Drug Developments, eds, Peters W, Richards WHG,. Berlin: Springer-Verlag, 1984; 225-265.
36. Langhorne J, Buffet P, Galinski M, Good M, Harty J, Leroy D, Mota MM, Pasini E, Renia L, Riley E, Stins M, Duffy P,. The relevance of non-human primate and rodent malaria models for humans. Malar J 2011; 10: 23.
37. Peters W, Robinson BL,. Handbook of Animal Models of Infection. San Diego, CA: Academic Press, 1999.
38. Thompson PE, Werbel LM,. Antimalarial Agents: Chemistry and Pharmacology. New York: Academic Press, 1972.
39. Gujjar R, El Mazouni F, White KL, White J, Creason S, Shackleford DM, Deng X, Charman WN, Bathurst I, Burrows J, Floyd DM, Matthews D, Buckner FS, Charman SA, Phillips MA, Rathod PK,. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem 2011; 54: 3935-3949.
40. Posner GH, Paik IH, Chang W, Borstnik K, Sinishtaj S, Rosenthal AS, Shapiro TA,. Malaria-infected mice are cured by a single dose of novel artemisinin derivatives. J Med Chem 2007; 50: 2516-2519.
41. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, Gonzalez-Paez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT,. Spiroindolones, a potent compound class for the treatment of malaria. Science 2010; 329: 1175-1180.
42. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN,. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004; 430: 900-904.
43. Thompson PE, Bayles A, Olszewski B,. Antimalarial activity of 2,4-diamino-6-[(3,4-dichlorobenzyl) nitros-amino] quinazoline (CI-679 base) and CI-679 acetate. Laboratory studies in mice and rhesus monkeys. Am J Trop Med Hyg 1970; 19: 12-26.
44. Slack RD, Mott BT, Woodard LE, Tripathi A, Sullivan D, Nenortas E, Girdwood SC, Shapiro TA, Posner GH,. Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine. J Med Chem 2012; 55: 291-296.
45. Moore BR, Page-Sharp M, Stoney JR, Ilett KF, Jago JD, Batty KT,. Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob Agents Chemother 2011; 55: 3899-3907.
46. Batty KT, Law AS, Stirling V, Moore BR,. Pharmacodynamics of doxycycline in a murine malaria model. Antimicrob Agents Chemother 2007; 51: 4477-4479.
47. Opsenica I, Opsenica D, Smith KS, Milhous WK, Solaja BA,. Chemical stability of the peroxide bond enables diversified synthesis of potent tetraoxane antimalarials. J Med Chem 2008; 51: 2261-2266.
48. Zaknoon F, Wein S, Krugliak M, Meir O, Rotem S, Ginsburg H, Vial H, Mor A,. Antiplasmodial properties of acyl-lysyl oligomers in culture and animal models of malaria. Antimicrob Agents Chemother 2011; 55: 3803-3811.
49. Meesters RJ, Hooff GP,. State-of-the-art dried blood spot analysis: an overview of recent advances and future trends. Bioanalysis 2013; 5: 2187-2208.
50. Rahavendran SV, Vekich S, Skor H, Batugo M, Nguyen L, Shetty B, Shen Z,. Discovery pharmacokinetic studies in mice using serial microsampling, dried blood spots and microbore LC-MS/MS. Bioanalysis 2012; 4: 1077-1095.
51. Dong Y, Wittlin S, Sriraghavan K, Chollet J, Charman SA, Charman WN, Scheurer C, Urwyler H, Santo Tomas J, Snyder C, Creek DJ, Morizzi J, Koltun M, Matile H, Wang X, Padmanilayam M, Tang Y, Dorn A, Brun R, Vennerstrom JL,. The structure-activity relationship of the antimalarial ozonide arterolane (OZ277). J Med Chem 2010; 53: 481-491.
52. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FC, Chollet J, Craft JC, Creek DJ, Dong Y, Matile H, Maurer M, Morizzi J, Nguyen T, Papastogiannidis P, Scheurer C, Shackleford DM, Sriraghavan K, Stingelin L, Tang Y, Urwyler H, Wang X, White KL, Wittlin S, Zhou L, Vennerstrom JL,. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 2011; 108: 4400-4405.
53. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D,. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med 2012; 9: e1001169.
54. Peters W, Fleck SL, Robinson BL, Stewart LB, Jefford CW,. The chemotherapy of rodent malaria. LX. The importance of formulation in evaluating the blood schizontocidal activity of some endoperoxide antimalarials. Ann Trop Med Parasitol 2002; 96: 559-573.
55. Janse CJ, Waters AP, Kos J, Lugt CB,. Comparison of in vivo and in vitro antimalarial activity of artemisinin, dihydroartemisinin and sodium artesunate in the Plasmodium berghei-rodent model. Int J Parasitol 1994; 24: 589-594.
56. Edstein MD, Kotecka BM, Ager AL, Smith KS, DiTusa CA, Diaz DS, Kyle DE, Schiehser GA, Jacobus DP, Rieckmann KH, O'Neil MT,. Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate-JPC2056-in cynomolgus monkeys using an in vivo in vitro model. J Antimicrob Chemother 2007; 60: 811-818.
57. Gibbons PL, Batty KT, Barrett PH, Davis TM, Ilett KF,. Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin. Int J Parasitol 2007; 37: 1569-1576.
58. Moore BR, Jago JD, Batty KT,. Plasmodium berghei: parasite clearance after treatment with dihydroartemisinin in an asplenic murine malaria model. Exp Parasitol 2008; 118: 458-467.
59. Moore BR, Batty KT, Andrzejewski C, Jago JD, Page-Sharp M, Ilett KF,. Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Antimicrob Agents Chemother 2008; 52: 306-311.
60. Moore BR, Ilett KF, Page-Sharp M, Jago JD, Batty KT,. Piperaquine pharmacodynamics and parasite viability in a murine malaria model. Antimicrob Agents Chemother 2009; 53: 2707-2713.
61. Patel K, Batty KT, Moore BR, Gibbons PL, Bulitta JB, Kirkpatrick CM,. Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria. Antimicrob Agents Chemother 2013; 57: 508-516.
62. Tarning J, Lindegardh N, Sandberg S, Day NJ, White NJ, Ashton M,. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J Pharm Sci 2008; 97: 3400-3410.
63. Ilett K, Batty KT,. Artemisinin and its derivatives. In: Antimicrobial Therapy and Vaccines, eds, Yu VL, Edwards G, Mckinnon PS, Peloquin CA, Morse G,. Pittsburgh, PA: ESun Technologies, 2005; 981-1002.
64. Price RN, Simpson JA, Davis TE,. Artemisinins. In: Kucers' the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic and Antiviral Drugs, ed., Grayson ML,. London: Hodder Arnold, 2010; 2090-2104.
65. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L,. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 2011; 10: 263.
66. White NJ,. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41: 1413-1422.
67. German PI, Aweeka FT,. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 2008; 47: 91-102.
68. White NJ,. The assessment of antimalarial drug efficacy. Trends Parasitol 2002; 18: 458-464.
69. Jamsen KM, Duffull SB, Tarning J, Lindegardh N, White NJ, Simpson JA,. Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Malar J 2011; 10: 181.
70. McGready R, Stepniewska K, Ward SA, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F,. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol 2006; 62: 367-371.
71. Morris CA, Onyamboko MA, Capparelli E, Koch MA, Atibu J, Lokomba V, Douoguih M, Hemingway-Foday J, Wesche D, Ryder RW, Bose C, Wright L, Tshefu AK, Meshnick S, Fleckenstein L,. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar J 2011; 10: 114.
72. Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansane A, Simpson JA, Morgan CC, White NJ, Kiechel JR,. Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J 2009; 8: 200.
73. Tarning J, Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Nuengchamnong N, Nosten F, Day NP, White NJ, Guerin PJ, Lindegardh N,. Population pharmacokinetics of artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malar J 2012; 11: 293.
74. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NP, White NJ, Nosten F, Lindegardh N,. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother 2012; 56: 1997-2007.
75. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Hutagalung R, Hae R, Singhasivanon P, White NJ, Nosten F,. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob Agents Chemother 2006; 50: 2281-2285.
76. Hietala SF, Martensson A, Ngasala B, Dahlstrom S, Lindegardh N, Annerberg A, Premji Z, Farnert A, Gil P, Bjorkman A, Ashton M,. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother 2010; 54: 4780-4788.
77. Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, Looareesuwan S, Aarons L, White NJ,. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther 1999; 66: 472-484.
78. Martin C, Gimenez F, Bangchang KN, Karbwang J, Wainer IW, Farinotti R,. Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. Eur J Clin Pharmacol 1994; 47: 85-87.
79. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ,. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44: 697-704.
80. Svensson US, Alin H, Karlsson MO, Bergqvist Y, Ashton M,. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol 2002; 58: 339-351.
81. Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, Annerberg A, Day NP, Stepniewska K, Singhasivanon P, White NJ, Nosten F,. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2009; 53: 3837-3846.
82. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D,. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004; 57: 253-262.
83. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NP, McGready R, Ashton M, Nosten F, White NJ,. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 2008; 52: 1052-1061.
84. Hoglund RM, Adam I, Hanpithakpong W, Ashton M, Lindegardh N, Day NP, White NJ, Nosten F, Tarning J,. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J 2012; 11: 398.
85. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ, Hanpithakpong W, Jongrak N, Day NP, White NJ, Nosten F, Ouedraogo JB, Lindegardh N,. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 2012; 91: 497-505.
86. Bell DJ, Nyirongo SK, Mukaka M, Molyneux ME, Winstanley PA, Ward SA,. Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. Clin Pharmacol Ther 2011; 89: 268-275.
87. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TM,. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother 2009; 53: 4368-4376.
88. Hietala SF, Bhattarai A, Msellem M, Roshammar D, Ali AS, Stromberg J, Hombhanje FW, Kaneko A, Bjorkman A, Ashton M,. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn 2007; 34: 669-686.
89. Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel JR,. Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. Antimicrob Agents Chemother 2010; 54: 2611-2617.
90. Tarning J, Chotsiri P, Jullien V, Rijken MJ, Bergstrand M, Cammas M, McGready R, Singhasivanon P, Day NP, White NJ, Nosten F, Lindegardh N,. Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob Agents Chemother 2012; 56: 5764-5773.
91. Hoshen MB, Stein WD, Ginsburg H,. Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Parasitology 1998; 116: 407-416.
92. Hoshen MB, Stein WD, Ginsburg H,. Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine. Parasitology 2002; 124: 9-15.
93. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ,. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother 2000; 44: 3414-3424.
94. Skinner TS, Manning LS, Johnston WA, Davis TM,. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol 1996; 26: 519-525.
95. Gravenor MB, van Hensbroek MB, Kwiatkowski D,. Estimating sequestered parasite population dynamics in cerebral malaria. Proc Natl Acad Sci U S A 1998; 95: 7620-7624.
96. Gordi T, Xie R, Jusko WJ,. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol 2005; 60: 594-604.
97. Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegardh N, Chotivanich K, Nosten F, Day NP, Socheat D, White NJ, Dondorp AM, White LJ,. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 2011; 108: 397-402.
98. Smith T, Dietz K, Vounatsou P, Muller I, English M, Marsh K,. Bayesian age-stage modelling of Plasmodium falciparum sequestered parasite loads in severe malaria patients. Parasitology 2004; 129: 289-299.
99. Ezzet F, Mull R, Karbwang J,. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46: 553-561.
100. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ,. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361: 455-467.
101. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F,. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379: 1960-1966.
102. Bethell D, Se Y, Lon C, Socheat D, Saunders D, Teja-Isavadharm P, Khemawoot P, Darapiseth S, Lin J, Sriwichai S, Kuntawungin W, Surasri S, Lee SJ, Sarim S, Tyner S, Smith B, Fukuda MM,. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis 2010; 51: e105-114.
103. Anderson BJ, Holford NH,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
104. Janse C, Waters AP,. The Plasmodium Berghei Research Model of Malaria. Leiden, The Netherlands: Leiden University Medical Centre, Leiden University Malaria Research Group (LMRG), 2002. Available at https://www.lumc.nl/con/1040/81028091348221/810281121192556/811070740182556/ (last accessed 17 December 2013).
105. World Health Organization. Methods and Techniques for Assessing Exposure to Antimalarial Drugs in Clinical Field Studies. Geneva, Switzerland: World Health Organization, 2010.
106. Simpson JA, Jamsen KM, Price RN, White NJ, Lindegardh N, Tarning J, Duffull SB,. Towards optimal design of anti-malarial pharmacokinetic studies. Malar J 2009; 8: 189.
107. Jamsen KM, Duffull SB, Tarning J, Lindegardh N, White NJ, Simpson JA,. Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria. Malar J 2012; 11: 143.
108. Na Bangchang K, Davis TM, Looareesuwan S, White NJ, Bunnag D, Karbwang J,. Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans R Soc Trop Med Hyg 1994; 88: 321-323.